Capital Essence's Investment Blog- 錢途集團 » Page not found  Mar 14  Comment 
Thursday bearish breakdown suggested that short-term overbought correction off the March high of 1883 on the S&P 500 index had evolved into an intermediate-term downtrend with downside target of 1828, which we’ve determined using the trend...
SeekingAlpha  Feb 13  Comment 
Vanda Pharmaceuticals (VNDA) Q4 2013 Earnings Call February 13, 2014 10:00 am ET Executives James Patrick Kelly - Chief Financial Officer, Principal Accounting Officer, Senior Vice President, Treasurer and Secretary Mihael H....
StreetInsider.com  Feb 13  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Vanda+Pharmaceuticals%2C+Inc.+%28VNDA%29+Misses+Q4+EPS+by+3c/9164257.html for the full story.
Benzinga  Feb 3  Comment 
Key Technology (NASDAQ: KTEC) plummeted 15.61% to $10.75. Key Technology's PEG ratio is 4.25. Galena Biopharma (NASDAQ: GALE) dropped 14.04% to $4.53. Galena Biopharma's trailing-twelve-month EPS is -$0.40. Vanda Pharmaceuticals (NASDAQ:...
StreetInsider.com  Jan 31  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Vanda+%28VNDA%29+Says+FDA+Approved+HETLIOZ/9112071.html for the full story.
StreetInsider.com  Dec 4  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Vanda+Pharma+%28VNDA%29+SVP%2C+CCO+Repella+to+Leave+Company/8945921.html for the full story.
Benzinga  Nov 27  Comment 
In a report published Wednesday, Piper Jaffray analyst Joshua E. Schimmer initiated coverage on Vanda Pharmaceuticals (NASDAQ: VNDA) with an Overweight rating and $21.00 price target. In the report, Piper Jaffray noted, “We are initiating,...
Benzinga  Nov 27  Comment 
In a report published Tuesday, Piper Jaffray analyst Joshua Schimmer maintained an Overweight rating on Vanda Pharmaceuticals (NASDAQ: VNDA) and maintained a price target of $21.00. In the report, Piper Jaffray says "We are assuming coverage...
StreetInsider.com  Nov 15  Comment 
52-Week High: Vanda Pharmaceuticals, Inc. (Nasdaq: VNDA) $16.45. Vanda rising over 26 percent on the session following news that an FDA panel voted overwhelmingly to recommend approval of HETLIOZ for the treatment of Non-24-Hour Disorder...

You may also be interested in articles related to Vanda Pharmaceuticals (VNDA):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki